CanSinoBIO Signs Innovative Vaccine Collaboration Agreement with SPIMACO

At the China-Saudi Investment Conference, CanSinoBIO, a company based in TEDA, signed a framework agreement for vaccine collaboration with Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO). The two parties will collaborate on the commercialization, joint research and development, clinical studies, and localized production of innovative vaccines. The focus will be on promoting CanSinoBIO’s Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), Menhycia®, in Saudi Arabia and other Middle Eastern and North African markets.

CanSinoBIO, established in 2009 in TEDA, possesses five innovative vaccine platform technologies, including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, and formulations and drug administration. They have established a product pipeline covering 17 types of innovative vaccines for more than 10 indications. SPIMACO, a leading pharmaceutical and medical supplies company in Saudi Arabia, operates in 16 countries. Mr. Jerome Cabannes, CEO of SPIMACO, stated, “The signing of this agreement will be a crucial step in assisting Saudi Arabia and the surrounding regions in building a comprehensive immune barrier for the entire population.”